STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER

Analysis of latest trials, comparing treatment schemes including nautica kad?n cüzdan chemotherapy with anti-EGFR monoclonal antibodies or bevacizumab is presented in this article.The data in these trials is inconsistent, but detailed analysis of FIRE-3 trial allows to distinguish a wild-type RAS patient group that benefits most from chemotherapy with cetuximab or corgi pup knife panitumumab as 1st line metastatic colorectal cancer treatment.A final analysis of this patient group in CALGB/SWOG 80 405 trial is pending.The RAS analysis is pivotal for choice of 1st line chemotherapy.